Function After Injection of Benign Bone Lesions with a Bioceramic

Fillingham, Yale A.; Lenart, Brett A.; Gitelis, Steven

doi:10.1007/s11999-012-2251-5

Cited by 47 publications

(37 citation statements)

References 25 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…He was successfully treated with complete PRO-DENSE removal, extensive irrigation and debridement, implantation of antibioticladen PMMA, and a 6-week course of intravenous antibiotics. In a series of 15 pa-tients treated with calcium sulfate reported by Kelly and Wilkins 20 and a series of 56 patients treated with PRO-DENSE reported by Fillingham et al, 21 1 case of infection in each study was successfully treated with irrigation and debridement without complete graft removal or antibiotic-laden PMMA.…”

Section: A 1b 1c 1dmentioning

confidence: 96%

“…To the authors' knowledge, 1 other report has examined the use of a CaSO 4 / CaPO 4 synthetic bone graft composite in the surgical management of primary bone tumors. Fillingham et al 21 reported 56 patients treated with PRO-DENSE after management of a variety of benign bone lesions. Most patients returned to normal function with high Musculoskeletal Tumor Society functional outcome scores at a mean follow-up of 42 months.…”

Section: D 2e 2fmentioning

confidence: 99%

“…The study did not report the timing or achievement of early functional recovery. 21 Few studies have reported bone defect reconstruction after intralesional curettage of benign bone tumors with other synthetic bone substitutes. Calcium sulfate alone, b-TCP alone, and CaSO 4 combined with hydroxyapatite were associated with high Musculoskeletal Tumor Society scores in retrospective series.…”

Section: D 2e 2fmentioning

confidence: 99%

See 2 more Smart Citations

Use of a Calcium Sulfate–Calcium Phosphate Synthetic Bone Graft Composite in the Surgical Management of Primary Bone Tumors

Evaniew

Tan²,

Parasu³

et al. 2013

Orthopedics

View full text Add to dashboard Cite

Benign primary bone tumors are commonly treated with intralesional curettage with or without the use of surgical adjuvants. The reconstructive approach to the resulting contained bone defects is controversial, and clinical practice is varied. Synthetic bone substitutes may provide early mechanical support while minimizing the risks of disease transmission, nonunion, infection, and donor-site morbidity. Limited data exists regarding the use of calcium sulfate-calcium phosphate composite bone substitute for this purpose. The authors retrospectively reviewed the clinical outcomes of 24 patients with benign primary bone tumors who underwent intralesional curettage followed by reconstruction with a calcium sulfate-calcium phosphate composite bone substitute. Mean follow-up was 23 months. The most common diagnosis was giant cell tumor of bone. Six patients had upper-extremity tumors and 18 had lower-extremity tumors. Mean preoperative radiographic tumor volume was 41.0 cm(3). Mean volume of PRO-DENSE (Wright Medical Technology, Arlington, Tennessee) used in each patient was 15.6 cm(3). Mean time to full weight bearing for all patients was 7.3 weeks. Two patients sustained local tumor recurrences. No postoperative fractures occurred, and no complications occurred related to the use of the calcium sulfate-calcium phosphate composite. One case of deep infection occurred secondary to wound breakdown. The use of a calcium sulfate-calcium phosphate composite was associated with rapid biological integration and an early return to activities of daily living, with no composite-related complications. This technique is a viable option in the reconstruction of cavitary bone defects following intralesional curettage of primary benign bone tumors.

show abstract

Section: A 1b 1c 1dmentioning

confidence: 96%

Section: D 2e 2fmentioning

confidence: 99%

Section: D 2e 2fmentioning

confidence: 99%

See 1 more Smart Citation

Use of a Calcium Sulfate–Calcium Phosphate Synthetic Bone Graft Composite in the Surgical Management of Primary Bone Tumors

Evaniew

Tan²,

Parasu³

et al. 2013

Orthopedics

View full text Add to dashboard Cite

show abstract

“…This composite has been used for benign bone tumour series and patients treated with this material reported high functional scores with low complication rates [25].…”

Section: Discussionmentioning

confidence: 99%

The use of an injectable calcium sulphate/calcium phosphate bioceramic in the treatment of osteonecrosis of the femoral head

Civinini

Biase

Carulli

et al. 2012

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

Purpose The purpose of our study is to describe the rationale, the surgical technique and the early clinical and radiographic results of the treatment of patients with early stage osteonecrosis of the femoral head (ONFH) by performing: core decompression, injection of autologous bone marrow concentrate and the use of a new composite injectable bone substitute (PRO-DENSE ® ), as a mechanical supplementation associated with decompression. Methods The study included 37 hips (31 patients, 14 females, 17 males; mean age 43.9 years, range 24-56 years) with stages IC-IIIA ONFH. The outcome was determined by the changes in the Harris hip score (HHS), by progression in radiographic stages and by the need for hip replacement. The mean follow-up was 20.6 months (range 12-32 months). Results At final follow-up the mean HHS increased from 68 points pre-operatively to 86 points post-operatively. The radiological results showed that 29 hips (78.4 %) improved or had no further collapse. The overall clinical success rate of the procedure was 86.5 %, with three conversions to THA, and a failure rate of only 3.3 % in the pre-collapse group. Conclusions We are encouraged by these early results using core decompression, injection of the autologous bone marrow concentrate and backfilling the defect with an injectable bioceramic for the treatment of early stages of ONFH; as far as a conclusion can be drawn from the current data, this treatment seems to relieve hip pain and prevent the progression of ONFH in the majority of the cases.

show abstract

“…[3][4][5][6][7][8][9][10][11] In 56 patients who underwent curettage and injection of bioceramic for benign bone tumours, the mean Musculoskeletal Tumor Society (MSTS) functional score was 29 after a mean follow-up of 42 months. 12 Autogenous bone grafts are widely used and remain the gold standard for grafting. 12 Owing to its limited supply and donor-site morbidity, the use of bone substitutes is increasingly popular.…”

mentioning

confidence: 99%

Bioceramic Bone Graft Substitute for Treatment of Unicameral Bone Cysts

Fillingham

Cvetanovich

Haughom

et al. 2016

J Orthop Surg (Hong Kong)

Self Cite

View full text Add to dashboard Cite

show abstract

Function After Injection of Benign Bone Lesions with a Bioceramic

Abstract: Background A novel calcium sulfate-calcium phosphate composite injectable bone graft substitute has been approved by the FDA for filling bone defects in a nonweightbearing application based on preclinical studies. Its utility has not been documented in the literature.

Cited by 47 publications

References 25 publications

Use of a Calcium Sulfate–Calcium Phosphate Synthetic Bone Graft Composite in the Surgical Management of Primary Bone Tumors

Use of a Calcium Sulfate–Calcium Phosphate Synthetic Bone Graft Composite in the Surgical Management of Primary Bone Tumors

The use of an injectable calcium sulphate/calcium phosphate bioceramic in the treatment of osteonecrosis of the femoral head

Bioceramic Bone Graft Substitute for Treatment of Unicameral Bone Cysts

Contact Info

Product

Resources

About